期刊文献+

原发性肝癌肝移植术后化疗效果的初步观察 被引量:5

Chemotherapy of Primary Liver Carcinoma undergoing Liver Transplantation
下载PDF
导出
摘要 目的:探讨原发性肝癌肝移植后化疗的安全性和疗效。方法:回顾性分析22例因原发性肝癌而行肝移植病人的临床资料,以求进一步探明肝癌的肝移植指征,术后化疗时机、化疗方案、化疗的副作用及化疗对近、远期生存率的影响。结果:2002年6月至2003年7月,共有22例原发性肝癌进行肝移植;18例最迟于术后5周内进行第1次全身化疗,累计完成化疗41次;其余4例因各种原因未行化疗,包括1例意外发现的癌和1例小肝癌。8例出现肝功能损害,6例发生白细胞减少,仅2例需重组人集落刺激生长因子治疗。结论:原发性肝癌是肝移植的一个主要适应证;结合术后化疗可延长复发时间,提高生存率;且病人可以安全耐受。 Objective: To explore the effect of systemic chemotherapy of primary liver carcinoma undergoing liver transplantation. Methods: All cases of primary liver carcionoma undergoing liver transplantation in our hospital were retrospectively analyzed. The indication for liver transplantation, the time and schedule of chemotherapy and its effect on short-term and long-term survival rate were studied. Results: From June 2002 to July 2003, 22 patients with primary hepatic carcinoma underwent liver transplantation. Eighteen patients received systemic chemotherapy every 4 weeks as tolerated, starting from the fifth postoperative week. Four cases did not have chemotherapy due to various reasons, including 1 case of accidentally discovered HCC and 1 case of small HCC. Among the patients receiving chemotherapy, 8 cases showed liver functional disorder, 6 had bone marrow depression, of witch only 2 cases need granulocyte colony-stimulating factor with no adverse effect on graft tolerance. Conclusions: Primary liver carcinoma remains one of the major indications of liver transplantation in China. Postoperative chemotherapy is usually well tolerated, and seems to deter recurrence and prolong survival in patients undergoing liver transplantation.
出处 《外科理论与实践》 2003年第6期448-450,共3页 Journal of Surgery Concepts & Practice
关键词 原发性肝癌 肝移植 术后化疗 安全性 手术指征 Primary liver carcinoma Liver transplantation Systemic chemotherapy
  • 相关文献

参考文献5

  • 1[1]Marsh JW, Dvorchik I, Iwatsuki S. Liver transplantation in the treatment of hepatocellular carcinoma[J]. J Hepatobiliary Pancreat Surg, 1998,5(1):24-28.
  • 2[2]Bechstein WO, Guckelberger O, Kling N, et al. Recurrence-free survival after liver transplantation for small hepatocellular carcinoma[J]. Transpl Int, 1998,11 (Suppl 1):S189-S192.
  • 3[3]Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters[J]. Ann Surg, 2002,235(4):533-539.
  • 4[4]Cherqui D, Piedbois P, Pierga JY, et al. Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study[J]. Cancer, 1994,73(11):2721-2726.
  • 5[5]Olthoff KM, Rosove MH, Shackleton CR, et al. Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 1995,221 (6):734-743.

同被引文献30

  • 1陈规划,陆敏强,蔡常洁,杨扬,何晓顺,朱晓峰.肝癌肝移植术后个体化化疗疗效初步分析[J].中华外科杂志,2004,42(17):1040-1043. 被引量:18
  • 2De-ChenWang Tong-LinZhang Shi-BingSong JiongYuan Dian-RongXiu Xiao-XiaYang.A report of 28 cases of 3-year follow-up after liver transplantation for advanced hepatocellular carcinoma[J].World Journal of Gastroenterology,2004,10(14):2134-2135. 被引量:4
  • 3张照辉,马力文,宋世兵,修典荣,王俊杰,杨晓霞,贾易木.肝癌肝移植术后辅助化疗的临床分析[J].中华肿瘤杂志,2005,27(1):45-47. 被引量:15
  • 4许世峰,刘军,杨凤辉,李光兵,公伟.Ⅲ期、Ⅳa期肝癌肝移植围术期辅助性化疗效果分析[J].山东医药,2005,45(17):3-4. 被引量:1
  • 5Freise CE, Ferrell L, Liu T et al. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma[J]. Transplantation, 1999, 67(4): 510-513.
  • 6Vivarelli M, Bellusci R, Cucchetti A, et al. Low recurrence rate of hepatocellular carcinoma after liver transplanlation: better patient seletion or lower immunosuppression[J]? Transplantion, 2002, 74(12):1746-1751.
  • 7Matsuda S, Moriguehi T, Koyasu S, et al. T lymphocyte activition signals for interleukin-2 production involve activition of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A [J]. J Biol Chem,1998, 273(20): 12378-12382.
  • 8Almawi WY, Melemedjian OK. Clinial and mechanistic defferences between FK506(tacrolimus) and cyclosporin A[J]. Nephrol Dial Transplant. 2000, 15(12): 1916-1918.
  • 9Shiraga K, Sakaguchi K, Senoh T, et al. Modulation of doxorubicin sensitivity by cyclosporine A in hapatocellular carcinoma cells and their doxorubicin-resistant sublines. J Gastroenterol Hepatol[J], 2001, 16:460-466.
  • 10Ito C, Ribeiro RC, Behm FG, et al. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood[J], 1998, 91(3): 1001-1007.

引证文献5

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部